Live Analyst Rating Changes 8803 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Hassan Al-Wakeel
BARC
Hassan Al-Wakeel
Barclays
Wall Street Analyst
Not yet ranked — too few measurable calls.
100%
Success Rate
+0.9%
Average Return
1 of 1 calls profitable · -22.6% vs benchmark
📈 Across the calls we could measure, roughly 100% of Hassan Al-Wakeel's ratings turned a profit when each position was held for 1 year — averaging +0.9% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

112 Buy 47 Hold 16 Sell
Hassan's Stock Coverage 18 ratings · 2026-07-16
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return
CH:STMN
Straumann Holding AG
 Jul 10, 2026 BUY Buy
+19.7% avg upside
15 analysts
$120.00
15.43% Upside
 ·
WILLF
Demant
 Jun 26, 2026 HOLD Strong Buy
-3.8% avg upside
19 analysts
$36.72
11.55% Downside
 ·
GB:SN
Smith & Nephew
 Jun 26, 2026 HOLD Strong Buy
+1205.0% avg upside
16 analysts
$1290.00
12.04% Upside
 ·
GB:0K9P
GN Store Nord
 Jun 26, 2026 BUY Hold
+162.3% avg upside
13 analysts
$123.00
34.97% Upside
 ·
GB:CTEC
ConvaTec
 Jun 23, 2026 BUY Strong Buy
+38.4% avg upside
17 analysts
$300.00
40.76% Upside
 ·
SE:EKTA.B
Elekta AB
 May 29, 2026 SELL Sell
+25.3% avg upside
12 analysts
$44.50
6.90% Downside
 ·
DE:SHL
Siemens Healthineers AG
 May 22, 2026 BUY Strong Buy
+43.5% avg upside
24 analysts
$50.00
43.84% Upside
 ·
CH:SOON
Sonova Holding AG
 May 19, 2026 SELL Sell
+8.0% avg upside
17 analysts
$175.00
15.61% Downside
 ·
GB:SPI
Spire Healthcare
 May 15, 2026 BUY Strong Buy
+34.6% avg upside
6 analysts
$275.00
25.93% Upside
 ·
FR:EL
EssilorLuxottica SA
 May 11, 2026 BUY Strong Buy
+13.0% avg upside
17 analysts
$300.00
78.35% Upside
 ·
NL:PHIA
Koninklijke Philips N.V.
 May 07, 2026 BUY Buy
+31.2% avg upside
21 analysts
$29.50
24.11% Upside
 ·
DE:FRE
Fresenius SE & Co. KGaA
 May 06, 2026 BUY Strong Buy
+22.9% avg upside
20 analysts
$57.00
36.55% Upside
 ·
DE:FME
Fresenius Medical Care AG & Co. KGaA
 May 05, 2026 HOLD Buy
+21.3% avg upside
22 analysts
$46.00
9.26% Upside
 ·
SE:VIMIAN
Vimian Group AB
 Apr 30, 2026 SELL Sell
-11.2% avg upside
2 analysts
$26.00
17.55% Downside
 ·
GB:0QBO
Coloplast A/S
 Apr 26, 2026 HOLD Buy
+81.1% avg upside
17 analysts
$500.00
24.66% Upside
 ·
GB:ONT
Oxford Nanopore Technologies PLC
 Mar 12, 2026 BUY Strong Buy
+80.4% avg upside
6 analysts
$170.00
49.80% Upside
 ·
IT:AMP
Amplifon S.p.A.
 Jul 31, 2025 BUY Hold
+142.6% avg upside
13 analysts
$20.50
90.25% Upside
 ·
FSNUY
Fresenius SE & Co
 Feb 18, 2019 HOLD Strong Buy
-12.6% avg upside
7 analysts
 — +0.9%
🔒 13 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Hassan Al-Wakeel — Frequently Asked Questions
How accurate are Hassan Al-Wakeel's stock ratings?
Based on the calls 13Foresight could measure, about 100% of Hassan's ratings were profitable over a one-year hold, with an average return of +0.9% per rating, or -22.6% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Hassan ranked on 13Foresight?
Hassan Al-Wakeel is currently ranked unranked . Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Hassan cover?
Hassan most recently has ratings on CH:STMN, WILLF, GB:SN, GB:0K9P, GB:CTEC, SE:EKTA.B, DE:SHL, CH:SOON, GB:SPI, FR:EL, NL:PHIA, DE:FRE and 6 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.